IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma

NCT07229417 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Endocrine Refractory
Triple Negative Invasive Lobular Carcinoma

Interventions

DRUG: Ivonescimab

Sponsor

M.D. Anderson Cancer Center